Pharmacyte Biotech Inc  

(Public, OTCMKTS:PMCB)   Watch this stock  
Find more results for PINK:NVLX
0.109
+0.001 (0.93%)
Delayed:   1:38PM EDT
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range 0.11 - 0.12
52 week 0.09 - 0.33
Open 0.11
Vol / Avg. 1.44M/2.26M
Mkt cap 77.15M
P/E     -
Div/yield     -
EPS -0.03
Shares 707.77M
Beta 1.45
Inst. own 0%

Key stats and ratios

Q1 (Jan '15) 2014
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -88.04% -447.04%
Return on average equity -92.61% -732.54%
Employees 4 -
CDP Score - -

Address

12510 Prosperity Dr Ste 310
SILVER SPRING, MD 20904-1643
United States - Map
+1-917-5952850 (Phone)
+1-917-5952851 (Fax)

Website links

Description

PharmaCyte Biotech, Inc., formerly Nuvilex, Inc., is a Biotechnology company. The Company utilizes a cellulose-based live cell encapsulation technology (Cell in-a-Box) to develop treatments for pancreatic cancer, breast cancer, brain cancer and diabetes. The Company operates independently and through wholly-owned subsidiaries. The Company has three operations: The first of these includes the cellulose-based live cell encapsulation technology. The second pertains to the work of its subsidiary, Medical Marijuana Sciences, Inc. (MMS). MMS focuses on ways to exploit the benefits of the live cell encapsulation technology in optimizing the anticancer effectiveness of constituents of Cannabis (cannabinoids) against cancers. The third segment consists of the Company’s nutraceutical formulations and their associated product names and information technology. The plan for this segment is to sell its nutraceutical formulations and associated information technology.

Officers and directors

Kenneth L. Waggoner Chairman of the Board, President, Chief Executive Officer, General Counsel
Age: 65
Robert Bowker President of Knock-Out Technologies, Inc.
Age: 65
Richard M. Goldfarb M.D. President of MedElite Inc
Age: 60
Gerald W. Crabtree Ph.D. Chief Operating Officer, Director
Age: 73
Walter H. Gunzburg Chief Scientific Officer
Thomas Liquard Director